INmune Bio (NASDAQ:INMB) Lowered to “Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of INmune Bio (NASDAQ:INMB) from a hold rating to a sell rating in a report published on Saturday morning.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of INmune Bio in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $18.00.

INmune Bio Trading Up 1.6%

Shares of NASDAQ:INMB opened at $1.91 on Friday. The company has a 50 day moving average of $1.76 and a 200 day moving average of $3.08. The stock has a market cap of $50.78 million, a P/E ratio of -0.90 and a beta of 0.91. INmune Bio has a 12 month low of $1.38 and a 12 month high of $11.64.

INmune Bio (NASDAQ:INMB) last announced its quarterly earnings results on Thursday, October 30th. The company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.07. On average, equities analysts forecast that INmune Bio will post -2.24 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Intech Investment Management LLC bought a new position in INmune Bio in the second quarter valued at $26,000. PFG Investments LLC bought a new position in shares of INmune Bio during the 2nd quarter valued at $27,000. Cary Street Partners Financial LLC bought a new stake in shares of INmune Bio in the third quarter worth about $29,000. Independent Advisor Alliance purchased a new position in shares of INmune Bio during the third quarter valued at approximately $30,000. Finally, Squarepoint Ops LLC purchased a new position in INmune Bio during the 3rd quarter valued at $30,000. 12.72% of the stock is currently owned by hedge funds and other institutional investors.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.